Trial Profile
A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992 50 mg once daily (BB) versus mFOLFOX7 alone as first-line therapy in patients with metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Afatinib; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 08 Apr 2022 Status changed from recruiting to completed.
- 23 Jun 2012 Additional location (Spain) added as reported by European Clinical Trials Database record.
- 10 Jul 2011 This trial is recruiting in France and Spain, but has discontinued in Germany.